{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T01:40:04Z","timestamp":1787708404788,"version":"build-2784847793"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,11]],"date-time":"2024-11-11T00:00:00Z","timestamp":1731283200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,11,11]],"date-time":"2024-11-11T00:00:00Z","timestamp":1731283200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100008021","name":"Bristol-Myers Squibb Company | Bristol-Myers Squibb Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008021","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Limited data exist on the effects of induction treatment in patients with newly diagnosed multiple myeloma (NDMM) and renal impairment (RI), who may also be ineligible for autologous stem cell transplant. This analysis investigated the impact of lenalidomide-bortezomib-dexamethasone (RVd) induction on renal function in patients from the Connect\u00ae MM Registry based on transplant status. Eligible patients were aged \u226518 years with symptomatic MM diagnosed \u22642 months before enrollment. Patients in this analysis received front-line RVd for \u22653 cycles and were grouped by transplant status and baseline renal function. As of August 4, 2021, 344 transplanted and 289 non-transplanted patients had received RVd for \u22653 cycles at induction. Improved renal function was observed at 3, 6, and 12 months in patients with all severities of RI at baseline. In patients with &gt;60 and \u226460 creatinine clearance mL\/min at baseline, median progression-free survival was 49.4 months and 47.6 months in transplanted patients and 35.7 months and 29.1 months in non-transplanted patients, respectively. These results provide real-world evidence that patients with NDMM and RI who receive front-line RVd for \u22653 cycles may have improved renal function regardless of transplant status, with renal function no longer affecting the long-term outcome. Clinical trial information: NCT01081028.<\/jats:p>","DOI":"10.1038\/s41408-024-01177-6","type":"journal-article","created":{"date-parts":[[2024,11,11]],"date-time":"2024-11-11T07:27:17Z","timestamp":1731310037000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Impact of lenalidomide-bortezomib-dexamethasone induction on patients with newly diagnosed multiple myeloma and renal impairment: Results from the Connect\u00ae MM Registry"],"prefix":"10.1038","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8377-8111","authenticated-orcid":false,"given":"Sikander","family":"Ailawadhi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8545-3292","authenticated-orcid":false,"given":"Hans C.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Omel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Toomey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James W.","family":"Hardin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina J.","family":"Gasparetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2934-6518","authenticated-orcid":false,"given":"Sundar","family":"Jagannath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3141-1518","authenticated-orcid":false,"given":"Robert M.","family":"Rifkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian G. M.","family":"Durie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohit","family":"Narang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard R.","family":"Terebelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prashant","family":"Joshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying-Ming","family":"Jou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Mouro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafat","family":"Abonour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,11]]},"reference":[{"key":"1177_CR1","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1159\/000442511","volume":"1","author":"P Yadav","year":"2016","unstructured":"Yadav P, Cook M, Cockwell P. Current trends of renal impairment in multiple myeloma. Kidney Dis (Basel). 2016;1:241\u201357.","journal-title":"Kidney Dis (Basel)"},{"key":"1177_CR2","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1200\/JCO.2015.65.0044","volume":"34","author":"MA Dimopoulos","year":"2016","unstructured":"Dimopoulos MA, Sonneveld P, Leung N, Merlini G, Ludwig H, Kastritis E, et al. International myeloma working group recommendations for the diagnosis and management of myeloma-related renal impairment. J Clin Oncol. 2016;34:1544\u201357.","journal-title":"J Clin Oncol"},{"key":"1177_CR3","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","volume":"15","author":"SV Rajkumar","year":"2014","unstructured":"Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15:e538\u201348.","journal-title":"Lancet Oncol"},{"key":"1177_CR4","doi-asserted-by":"publisher","DOI":"10.1177\/20406207221088458","volume":"13","author":"MA Dimopoulos","year":"2022","unstructured":"Dimopoulos MA, Mikhael J, Terpos E, Leleu X, Moreau P, Blade J, et al. An overview of treatment options for patients with relapsed\/refractory multiple myeloma and renal impairment. Ther Adv Hematol. 2022;13:20406207221088458.","journal-title":"Ther Adv Hematol"},{"key":"1177_CR5","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1080\/17474086.2016.1210003","volume":"9","author":"D Fotiou","year":"2016","unstructured":"Fotiou D, Dimopoulos MA, Kastritis E. Managing renal complications in multiple myeloma. Expert Rev Hematol. 2016;9:839\u201350.","journal-title":"Expert Rev Hematol"},{"key":"1177_CR6","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1080\/10428194.2020.1867725","volume":"62","author":"GR Mohyuddin","year":"2021","unstructured":"Mohyuddin GR, Koehn K, Shune L, Aziz M, Abdallah AO, McClune B, et al. Renal insufficiency in multiple myeloma: a systematic review and meta-analysis of all randomized trials from 2005-2019. Leuk Lymphoma. 2021;62:1386\u201395.","journal-title":"Leuk Lymphoma"},{"key":"1177_CR7","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1093\/ndt\/gfz211","volume":"36","author":"M Courant","year":"2021","unstructured":"Courant M, Orazio S, Monnereau A, Preterre J, Combe C, Rigothier C. Incidence, prognostic impact and clinical outcomes of renal impairment in patients with multiple myeloma: a population-based registry. Nephrol Dial Transplant. 2021;36:482\u201390.","journal-title":"Nephrol Dial Transplant"},{"key":"1177_CR8","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1001\/archinte.158.17.1889","volume":"158","author":"J Blade","year":"1998","unstructured":"Blade J, Fernandez-Llama P, Bosch F, Montoliu J, Lens XM, Montoto S, et al. Renal failure in multiple myeloma: presenting features and predictors of outcome in 94 patients from a single institution. Arch Intern Med. 1998;158:1889\u201393.","journal-title":"Arch Intern Med"},{"key":"1177_CR9","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1182\/blood-2020-140937","volume":"136","author":"K Ramasamy","year":"2020","unstructured":"Ramasamy K, Iqbal G, Drayson MT, Brouwer R, Varghese S, Schey S, et al. Quality of life data from a prospective randomised trial of newly diagnosed myeloma patients with renal failure: optimal trial. Blood. 2020;136:5\u20136.","journal-title":"Blood"},{"key":"1177_CR10","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/S0140-6736(16)31594-X","volume":"389","author":"BG Durie","year":"2017","unstructured":"Durie BG, Hoering A, Abidi MH, Rajkumar SV, Epstein J, Kahanic SP, et al. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. Lancet. 2017;389:519\u201327.","journal-title":"Lancet"},{"key":"1177_CR11","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.clml.2017.06.013","volume":"17","author":"JJ Shah","year":"2017","unstructured":"Shah JJ, Abonour R, Gasparetto C, Hardin JW, Toomey K, Narang M, et al. Analysis of common eligibility criteria of randomized controlled trials in newly diagnosed multiple myeloma patients and extrapolating outcomes. Clin Lymphoma Myeloma Leuk. 2017;17:575\u201383. e2","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"1177_CR12","unstructured":"Revlimid (lenalidomide) [package insert]. Princeton, NJ: Celgene Corporation, a Bristol Myers Squibb company; Revised 2023."},{"key":"1177_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-018-0110-7","volume":"8","author":"J Mikhael","year":"2018","unstructured":"Mikhael J, Manola J, Dueck AC, Hayman S, Oettel K, Kanate AS, et al. Lenalidomide and dexamethasone in patients with relapsed multiple myeloma and impaired renal function: PrE1003, a PrECOG study. Blood Cancer J. 2018;8:86.","journal-title":"Blood Cancer J"},{"key":"1177_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-018-4926-0","volume":"18","author":"M Antlanger","year":"2018","unstructured":"Antlanger M, Dust T, Reiter T, Bohm A, Lamm WW, Gornicec M, et al. Impact of renal impairment on outcomes after autologous stem cell transplantation in multiple myeloma: a multi-center, retrospective cohort study. BMC Cancer. 2018;18:1008.","journal-title":"BMC Cancer"},{"key":"1177_CR15","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/j.clml.2014.12.002","volume":"15","author":"RM Rifkin","year":"2015","unstructured":"Rifkin RM, Abonour R, Terebelo H, Shah JJ, Gasparetto C, Hardin J, et al. Connect MM registry: the importance of establishing baseline disease characteristics. Clin Lymphoma Myeloma Leuk. 2015;15:368\u201376.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"1177_CR16","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.clml.2018.04.007","volume":"18","author":"S Jagannath","year":"2018","unstructured":"Jagannath S, Abonour R, Durie BGM, Gasparetto C, Hardin JW, Narang M, et al. Heterogeneity of second-line treatment for patients with multiple myeloma in the connect MM registry (2010-2016). Clin Lymphoma Myeloma Leuk. 2018;18:480\u20135.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"1177_CR17","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1182\/bloodadvances.2018017186","volume":"2","author":"S Jagannath","year":"2018","unstructured":"Jagannath S, Abonour R, Durie BGM, Narang M, Terebelo HR, Gasparetto CJ, et al. Impact of post-ASCT maintenance therapy on outcomes in patients with newly diagnosed multiple myeloma in Connect MM. Blood Adv. 2018;2:1608\u201315.","journal-title":"Blood Adv"},{"key":"1177_CR18","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.1007\/s00277-018-3446-y","volume":"97","author":"R Abonour","year":"2018","unstructured":"Abonour R, Wagner L, Durie BGM, Jagannath S, Narang M, Terebelo HR, et al. Impact of post-transplantation maintenance therapy on health-related quality of life in patients with multiple myeloma: data from the Connect\u00ae MM Registry. Ann Hematol. 2018;97:2425\u201336.","journal-title":"Ann Hematol"},{"key":"1177_CR19","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1111\/bjh.17131","volume":"193","author":"R Abonour","year":"2021","unstructured":"Abonour R, Rifkin RM, Gasparetto C, Toomey K, Durie BGM, Hardin JW, et al. Effect of initial treatment on health-related quality of life in patients with newly diagnosed multiple myeloma without immediate stem cell transplant intent: results from the Connect\u00ae MM Registry. Br J Haematol. 2021;193:93\u2013100.","journal-title":"Br J Haematol"},{"key":"1177_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00524-1","volume":"11","author":"HC Lee","year":"2021","unstructured":"Lee HC, Ailawadhi S, Gasparetto CJ, Jagannath S, Rifkin RM, Durie BGM, et al. Treatment patterns and outcomes in elderly patients with newly diagnosed multiple myeloma: results from the Connect\u00ae MM Registry. Blood Cancer J. 2021;11:134.","journal-title":"Blood Cancer J"},{"key":"1177_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-022-09980-9","volume":"22","author":"R Medhekar","year":"2022","unstructured":"Medhekar R, Ran T, Fu AZ, Patel S, Kaila S. Real-world patient characteristics and treatment outcomes among nontransplanted multiple myeloma patients who received Bortezomib in combination with Lenalidomide and Dexamethasone as first line of therapy in the United States. BMC Cancer. 2022;22:901.","journal-title":"BMC Cancer"},{"key":"1177_CR22","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1182\/blood.2020005288","volume":"136","author":"PM Voorhees","year":"2020","unstructured":"Voorhees PM, Kaufman JL, Laubach J, Sborov DW, Reeves B, Rodriguez C, et al. Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial. Blood. 2020;136:936\u201345.","journal-title":"Blood"},{"key":"1177_CR23","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/j.clml.2019.06.007","volume":"19","author":"A Chari","year":"2019","unstructured":"Chari A, Parikh K, Ni Q, Abouzaid S. Treatment patterns and clinical and economic outcomes in patients with newly diagnosed multiple myeloma treated with lenalidomide- and\/or bortezomib-containing regimens without stem cell transplant in a real-world setting. Clin Lymphoma Myeloma Leuk. 2019;19:645\u201355.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"1177_CR24","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1002\/cncr.20888","volume":"103","author":"S Jagannath","year":"2005","unstructured":"Jagannath S, Barlogie B, Berenson JR, Singhal S, Alexanian R, Srkalovic G, et al. Bortezomib in recurrent and\/or refractory multiple myeloma. Initial clinical experience in patients with impared renal function. Cancer. 2005;103:1195\u2013200.","journal-title":"Cancer"},{"key":"1177_CR25","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/leu.2008.291","volume":"23","author":"RA Kyle","year":"2009","unstructured":"Kyle RA, Rajkumar SV. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia. 2009;23:3\u20139.","journal-title":"Leukemia"},{"key":"1177_CR26","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1093\/biomet\/73.1.13","volume":"73","author":"K-Y Liang","year":"1986","unstructured":"Liang K-Y, Zeger SL. Longitudinal data analysis using generalized linear models. Biometrika. 1986;73:13\u201322.","journal-title":"Biometrika"},{"key":"1177_CR27","doi-asserted-by":"publisher","first-page":"121","DOI":"10.2307\/2531248","volume":"42","author":"SL Zeger","year":"1986","unstructured":"Zeger SL, Liang KY. Longitudinal data analysis for discrete and continuous outcomes. Biometrics. 1986;42:121\u201330.","journal-title":"Biometrics"},{"key":"1177_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-0273-x","volume":"10","author":"MA Dimopoulos","year":"2020","unstructured":"Dimopoulos MA, Jakubowiak AJ, McCarthy PL, Orlowski RZ, Attal M, Blad\u00e9 J, et al. Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma. Blood Cancer J. 2020;10:17.","journal-title":"Blood Cancer J"},{"key":"1177_CR29","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1002\/ajh.26512","volume":"97","author":"U Goel","year":"2022","unstructured":"Goel U, Usmani S, Kumar S. Current approaches to management of newly diagnosed multiple myeloma. Am J Hematol. 2022;97:S3\u2013s25.","journal-title":"Am J Hematol"},{"key":"1177_CR30","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.3390\/jpm12091451","volume":"12","author":"A Gozzetti","year":"2022","unstructured":"Gozzetti A, Bocchia M. Steps towards a Multiple Myeloma Cure? J Pers Med. 2022;12:1451.","journal-title":"J Pers Med"},{"key":"1177_CR31","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1038\/leu.2013.313","volume":"28","author":"SK Kumar","year":"2014","unstructured":"Kumar SK, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Pandey S, et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia. 2014;28:1122\u20138.","journal-title":"Leukemia"},{"key":"1177_CR32","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1093\/annonc\/mdt483","volume":"25","author":"MA Dimopoulos","year":"2014","unstructured":"Dimopoulos MA, Delimpasi S, Katodritou E, Vassou A, Kyrtsonis MC, Repousis P, et al. Significant improvement in the survival of patients with multiple myeloma presenting with severe renal impairment after the introduction of novel agents. Ann Oncol. 2014;25:195\u2013200.","journal-title":"Ann Oncol"},{"key":"1177_CR33","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.1016\/j.ekir.2022.06.005","volume":"7","author":"B Sprangers","year":"2022","unstructured":"Sprangers B, Perazella MA, Lichtman SM, Rosner MH, Jhaveri KD. Improving cancer care for patients with CKD: the need for changes in clinical trials. Kidney Int Rep. 2022;7:1939\u201350.","journal-title":"Kidney Int Rep"},{"key":"1177_CR34","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1177\/0091270007309563","volume":"47","author":"N Chen","year":"2007","unstructured":"Chen N, Lau H, Kong L, Kumar G, Zeldis JB, Knight R, et al. Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis. J Clin Pharmacol. 2007;47:1466\u201375.","journal-title":"J Clin Pharmacol"},{"key":"1177_CR35","doi-asserted-by":"publisher","first-page":"363","DOI":"10.3324\/haematol.2015.133629","volume":"101","author":"MA Dimopoulos","year":"2016","unstructured":"Dimopoulos MA, Cheung MC, Roussel M, Liu T, Gamberi B, Kolb B, et al. Impact of renal impairment on outcomes with lenalidomide and dexamethasone treatment in the FIRST trial, a randomized, open-label phase 3 trial in transplant-ineligible patients with multiple myeloma. Haematologica. 2016;101:363\u201370.","journal-title":"Haematologica"},{"key":"1177_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1600-0609.2010.01432.x","volume":"85","author":"MA Dimopoulos","year":"2010","unstructured":"Dimopoulos MA, Christoulas D, Roussou M, Kastritis E, Migkou M, Gavriatopoulou M, et al. Lenalidomide and dexamethasone for the treatment of refractory\/relapsed multiple myeloma: dosing of lenalidomide according to renal function and effect on renal impairment. Eur J Haematol. 2010;85:1\u20135.","journal-title":"Eur J Haematol"},{"key":"1177_CR37","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1177\/10600280221087218","volume":"57","author":"E Salama","year":"2023","unstructured":"Salama E, Lam S, Gonsalves WI, Tzachanis D, Momper JD, M Saunders I. Estimation of kidney function in patients with multiple myeloma: implications for lenalidomide dosing. Ann Pharmacother. 2023;57:29\u201335.","journal-title":"Ann Pharmacother"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-024-01177-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-024-01177-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-024-01177-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,11]],"date-time":"2024-11-11T19:02:31Z","timestamp":1731351751000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-024-01177-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,11]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1177"],"URL":"https:\/\/doi.org\/10.1038\/s41408-024-01177-6","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,11]]},"assertion":[{"value":"13 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Sikander Ailawadhi reports serving on a scientific steering committee for Bristol Myers Squibb; consulting fees from BeiGene, Bristol Myers Squibb, Cellectar, GSK, Janssen, Pfizer, Regeneron, Sanofi, and Takeda; and research funding from AbbVie, Amgen, Ascentage, Bristol Myers Squibb, Cellectar, GSK, Janssen, Pharmacyclics, and Sanofi. Hans C. Lee reports serving on a scientific steering committee for Bristol Myers Squibb; consulting fees from Allogene, Bristol Myers Squibb, Genentech, GSK, Janssen, Monte Rosa Therapeutics, Pfizer, Regeneron, Sanofi, and Takeda; and grants or contracts from Amgen, Bristol Myers Squibb, GSK, Janssen, Regeneron, and Takeda. James Omel, Kathleen Toomey, James W. Hardin, Brian G.M. Durie, Mohit Narang, Howard R. Terebelo, and Rafat Abonour report serving on a scientific steering committee for Bristol Myers Squibb. Cristina J. Gasparetto reports serving on a scientific steering committee for Bristol Myers Squibb; support for travel from Bristol Myers Squibb, Karyopharm, and Sanofi; advisory role for Bristol Myers Squibb, Janssen, and Pfizer; and for Bristol Myers Squibb, Karyopharm, and Sanofi. Sundar Jagannath reports serving on a scientific steering committee for Bristol Myers Squibb; consulting fees from Bristol Myers Squibb, Janssen, Karyopharm Therapeutics, Legend Biotech, Regeneron Sanofi, and Takeda; support for travel from American Society of Clinical Oncology, American Society of Hematology (ASH), and International Myeloma Society (IMS); participation on data safety monitoring boards for Bristol Myers Squibb, Janssen, and Sanofi; and leadership or fiduciary role for ASH, IMS, and Society of Hematologic Oncology. Robert M. Rifkin reports serving on a scientific steering committee for Bristol Myers Squibb; employment, stock, and other ownership interests with McKesson; participation on data safety monitoring board for CARsgen; and advisory role with Amgen, Bristol Myers Squibb; Coherus BioSciences, Genmab, Fresenius Kabi, and Janssen. Ying-Ming Jou reports employment and stock and other ownership interests with Bristol Myers Squibb. Prashant Joshi, Jorge Mouro, and Edward Yu are former employees of Bristol Myers Squibb.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"198"}}